Several anti-HGF/c-MET antibodies, such as onartuzumab, tepotinib, capmatinib, and tivantinib are already in the clinical stage of HCC treatment evaluation (NCT01897038, NCT02115373, NCT01737827, NCT02029157). This evidence concerns the gene HGF and hepatocellular carcinoma.